HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Toshio Nishikimi Selected Research

Adrenomedullin

1/2018Adrenomedullin as a Biomarker of Heart Failure.
2/2014Epicardial-derived adrenomedullin drives cardiac hyperplasia during embryogenesis.
6/2013Adrenomedullin in cardiovascular disease: a useful biomarker, its pathological roles and therapeutic application.
12/2010Greater expression of inflammatory cytokines, adrenomedullin, and natriuretic peptide receptor-C in epicardial adipose tissue in coronary artery disease.
5/2009Effects of long-term intravenous administration of adrenomedullin (AM) plus hANP therapy in acute decompensated heart failure: a pilot study.
2/2007Adrenomedullin gene expression differences in mice do not affect blood pressure but modulate hypertension-induced pathology in males.
1/2007Adrenomedullin in the kidney-renal physiological and pathophysiological roles.
10/2006Chronic effect of combined treatment with omapatrilat and adrenomedullin on the progression of heart failure in rats.
7/2005Up-regulated synthesis of mature-type adrenomedullin in coronary circulation immediately after reperfusion in patients with anterior acute myocardial infarction.
7/2005Cardiac adrenomedullin: its role in cardiac hypertrophy and heart failure.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Toshio Nishikimi Research Topics

Disease

37Heart Failure
01/2022 - 11/2002
11Cardiomegaly (Heart Hypertrophy)
12/2013 - 10/2002
8Fibrosis (Cirrhosis)
01/2016 - 11/2002
8Hypertension (High Blood Pressure)
10/2010 - 06/2002
6Hypertrophy
12/2013 - 10/2002
5Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
02/2018 - 03/2003
5Proteinuria
09/2008 - 09/2004
4Pheochromocytoma
01/2018 - 11/2002
3Cardiovascular Diseases (Cardiovascular Disease)
06/2013 - 10/2010
3Heart Diseases (Heart Disease)
05/2012 - 06/2002
3Ureteral Obstruction
09/2010 - 01/2006
3Nephrosclerosis
09/2008 - 09/2004
3Stroke (Strokes)
05/2007 - 06/2003
2Atrial Fibrillation
10/2021 - 01/2002
2Inflammation (Inflammations)
10/2021 - 09/2010
2Infections
04/2021 - 02/2003
2Sudden Death
01/2016 - 05/2013
2Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
10/2014 - 05/2013
2Chronic Kidney Failure (Chronic Renal Failure)
01/2014 - 01/2012
2Coronary Artery Disease (Coronary Atherosclerosis)
12/2010 - 06/2004
2Myocardial Infarction
06/2007 - 07/2005
2Renal Insufficiency (Renal Failure)
01/2007 - 06/2002
2Body Weight (Weight, Body)
02/2006 - 06/2003
2Fistula
04/2005 - 11/2002
2Malignant Hypertension
04/2003 - 07/2002
1COVID-19
04/2022
1Hyperthyroidism
10/2021
1Dyspnea (Shortness of Breath)
10/2021
1Acute Coronary Syndrome
10/2021
1Pericardial Effusion
10/2021
1Ischemia
10/2021
1Obesity
10/2021
1Human Influenza (Influenza)
04/2021
1Malnutrition (Nutritional Deficiencies)
01/2021
1Hip Fractures (Intertrochanteric Fractures)
01/2021
1Cardio-Renal Syndrome
01/2019
1Gastric Fistula
01/2018
1Death (Near-Death Experience)
10/2014
1Hyperplasia
02/2014
1Cardiac Sudden Death (Sudden Cardiac Arrest)
12/2013
1Ventricular Tachycardia
05/2013
1Neointima
11/2012

Drug/Important Bio-Agent (IBA)

28AdrenomedullinIBA
01/2018 - 02/2002
18Brain Natriuretic Peptide (Natrecor)FDA Link
12/2021 - 04/2004
14Atrial Natriuretic Factor (ANF)IBA
01/2019 - 01/2002
10Messenger RNA (mRNA)IBA
09/2015 - 12/2002
9Biomarkers (Surrogate Marker)IBA
10/2021 - 01/2002
8Natriuretic PeptidesIBA
01/2019 - 11/2002
8Peptides (Polypeptides)IBA
01/2018 - 07/2005
6pro-brain natriuretic peptide (1-76)IBA
10/2021 - 01/2012
6CollagenIBA
09/2010 - 01/2002
5Glycine (Aminoacetic Acid)FDA LinkGeneric
01/2018 - 11/2002
5rho-Associated KinasesIBA
09/2010 - 09/2004
4ReninIBA
01/2016 - 04/2005
4fasudil (AT 877)IBA
09/2010 - 09/2004
4Transforming Growth Factor beta (TGF-beta)IBA
09/2010 - 09/2004
4SaltsIBA
05/2007 - 12/2002
3CytokinesIBA
10/2021 - 12/2010
3atrial natriuretic factor receptor AIBA
04/2009 - 06/2003
3CreatinineIBA
09/2008 - 09/2004
3DiureticsIBA
02/2006 - 06/2003
2Indicators and Reagents (Reagents)IBA
12/2021 - 02/2003
2Hormones (Hormone)IBA
02/2018 - 01/2018
2Guanosine Monophosphate (5' Guanylic Acid)IBA
10/2017 - 04/2005
2Type 1 Angiotensin ReceptorIBA
01/2016 - 12/2013
2Apolipoproteins E (ApoE)IBA
11/2012 - 06/2003
2Pharmaceutical PreparationsIBA
10/2010 - 05/2009
2Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
09/2010 - 06/2003
2Nitric Oxide Synthase (NO Synthase)IBA
06/2006 - 05/2005
2Oxidoreductases (Dehydrogenase)IBA
06/2006 - 10/2002
2AldosteroneIBA
02/2006 - 04/2005
2SodiumIBA
05/2005 - 04/2005
2Calcitonin Receptor-Like ProteinIBA
01/2005 - 02/2003
2N-terminal proatrial natriuretic peptideIBA
08/2004 - 04/2004
2LigandsIBA
06/2003 - 04/2003
1GTP-Binding Proteins (G-Protein)IBA
01/2022
1sacubitril and valsartan sodium hydrate drug combinationIBA
10/2021
1GlycoconjugatesIBA
04/2021
1Connexin 43 (Connexin43)IBA
01/2016
1FurinIBA
09/2015
1NitrendipineIBA
10/2014
1cilnidipineIBA
10/2014
1Angiotensin IIIBA
12/2013
1AcidsIBA
06/2013
1IvabradineIBA
05/2013
1RE1-silencing transcription factorIBA
05/2013
1CCG 1423IBA
11/2012
1AdipokinesIBA
12/2010
1Biological ProductsIBA
10/2010
1Surface Antigens (Surface Antigen)IBA
10/2010
1Endothelin Receptors (Endothelin Receptor)IBA
10/2010
1Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
10/2010
1Angiotensin Receptor AntagonistsIBA
10/2010
1Drinking WaterIBA
09/2010
1Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
09/2010

Therapy/Procedure

5Therapeutics
05/2012 - 11/2003
3Activities of Daily Living (ADL)
04/2022 - 01/2020
2Renal Dialysis (Hemodialysis)
01/2014 - 11/2002
1Prostheses and Implants (Prosthesis)
01/2018
1Enteral Nutrition (Feeding, Tube)
01/2018